144 related articles for article (PubMed ID: 29601247)
21. Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer.
Torregrosa-Maicas MD; Del Barco-Berrón S; Cotes-Sanchís A; Lema-Roso L; Servitja-Tormo S; Gironés-Sarrió R
Clin Transl Oncol; 2022 Jun; 24(6):1033-1046. PubMed ID: 35103908
[TBL] [Abstract][Full Text] [Related]
22. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
[TBL] [Abstract][Full Text] [Related]
23. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
24. Management of primary and advanced breast cancer in older unfit patients (medical treatment).
Aapro M; Monfardini S; Jirillo A; Basso U
Cancer Treat Rev; 2009 Oct; 35(6):503-8. PubMed ID: 19762156
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Freedman RA; Tolaney SM
Breast Cancer Res Treat; 2018 Feb; 167(3):607-614. PubMed ID: 29103175
[TBL] [Abstract][Full Text] [Related]
26. Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer.
Lee SY; Seo JH
Biomed Res Int; 2018; 2018():6074808. PubMed ID: 29581979
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
28. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
29. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Diaby V; Tawk R; Sanogo V; Xiao H; Montero AJ
Breast Cancer Res Treat; 2015 May; 151(1):27-40. PubMed ID: 25893588
[TBL] [Abstract][Full Text] [Related]
30. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
32. An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients.
Oruç Z; Kaplan MA; Arslan Ç
Expert Opin Pharmacother; 2018 Aug; 19(12):1305-1316. PubMed ID: 30129373
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
[TBL] [Abstract][Full Text] [Related]
35. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
Mahtani RL; Stein A; Vogel CL
Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemotherapy in elderly patients with breast cancer: key challenges.
Pondé N; Dal Lago L; Azim HA
Expert Rev Anticancer Ther; 2016 Jun; 16(6):661-71. PubMed ID: 27010772
[TBL] [Abstract][Full Text] [Related]
37. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Finn RS; Press MF; Dering J; O'Rourke L; Florance A; Ellis C; Martin AM; Johnston S
Clin Cancer Res; 2014 Feb; 20(3):736-43. PubMed ID: 24198242
[TBL] [Abstract][Full Text] [Related]
38. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies.
Brufsky AM
Cancer Treat Rev; 2017 Sep; 59():22-32. PubMed ID: 28719836
[TBL] [Abstract][Full Text] [Related]
39. Effect of age on drug metabolism in women with breast cancer.
Singh JC; Lichtman SM
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):757-66. PubMed ID: 25940027
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
